Multicenter, Open-label, Phase II Safety and Efficacy Study of All-oral Combination Narlaprevir/Ritonavir and Daclatasvir Administered for 12 Weeks in Patients With Genotype 1b Chronic Hepatitis C
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Daclatasvir (Primary) ; Narlaprevir (Primary) ; Ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors R-Pharm
Most Recent Events
- 18 Dec 2018 Status changed from active, no longer recruiting to completed.
- 04 Apr 2018 New trial record